Primary Hyperaldosteronism
13
2
3
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
Tissue K+ in Primary Hyperaldosteronism
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)
Dynamic Hormone Diagnostics in Endocrine Disease
Radiofrequency Endoscopic Ablation With Ultrasound Guidance: a Non-surgical Treatment for Aldosterone-producing Adenomas
A Prospective Cohort Study for Patients With Adrenal Diseases
11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism
Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Intraoperative Analysis of Cortisol During Adrenal Vein Sampling
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism